Trial · NCT02436889

Treatment of Incontinence Without Memory Problems

NCT02436889, Phase 4, Completed, University of California, San Francisco; results first posted 2019-04-16

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Treatment of Incontinence Without Memory Problems. Trials, record NCT02436889. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02436889

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Treatment of Incontinence Without Memory Problems
NCT number: NCT02436889
Status: Completed
Phases: Phase 4
Enrollment: 23 participants, actual
Lead sponsor: University of California, San Francisco
Conditions: Urge Incontinence, Urinary Incontinence, Urge
Interventions: Mirabegron, Tolterodine Tartrate
First posted: 2015-05-07
Last updated: 2019-04-16
Results first posted: 2019-04-16

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	The Number of Participants Who Completed and Discontinued the Study	Baseline to Week 8	Feasibility - Assessment of retention rates.
Secondary	Change From Baseline in California Verbal Learning Test (CVLT) Score at 8 Weeks	Baseline to Week 8	Range of 0-80, with the higher the score the better.
Secondary	Change From Baseline in Trail Making Test, Trail A Score at 8 Weeks	Baseline and 8 weeks	Trail Making Test, Trail A Time, Range 0-150 seconds, Lower score indicates better functioning
Secondary	Change From Baseline in Short Physical Performance Battery (SPPB) Score at 8 Weeks	Baseline to Week 8	Physical function/mobility, Range 0-12, the higher the score the better.
Secondary	Change From Baseline in Total Urinary Incontinence Frequency Measured by a Voiding Diary at 8 Weeks	Baseline to Week 8	Study participants record number of urinary incontinence episodes in a voiding diary. The total urinary incontinence frequency is the sum of urinary incontinence episodes per day.
Secondary	Change From Baseline in Urge Incontinence Episodes Per Day on a Voiding Diary at 8 Weeks.	Baseline and 8 weeks	The sum of urge type incontinence episodes reported by participants on a voiding diary per day.

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	The Number of Participants Who Completed and Discontinued the Study	Baseline to Week 8		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Change From Baseline in California Verbal Learning Test (CVLT) Score at 8 Weeks	Baseline to Week 8	Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.	Score on a Scale	MEAN
SECONDARY	Change From Baseline in Trail Making Test, Trail A Score at 8 Weeks	Baseline and 8 weeks	Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.	seconds	MEAN
SECONDARY	Change From Baseline in Short Physical Performance Battery (SPPB) Score at 8 Weeks	Baseline to Week 8	Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.	score on a scale	MEAN
SECONDARY	Change From Baseline in Total Urinary Incontinence Frequency Measured by a Voiding Diary at 8 Weeks	Baseline to Week 8	Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.	episodes per day	MEAN
SECONDARY	Change From Baseline in Urge Incontinence Episodes Per Day on a Voiding Diary at 8 Weeks.	Baseline and 8 weeks	Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.	episodes per day	MEAN

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
The Number of Participants Who Completed and Discontinued the Study	Mirabegron	Completed study	11		Participants
The Number of Participants Who Completed and Discontinued the Study	Tolterodine Tartrate	Completed study	10		Participants
The Number of Participants Who Completed and Discontinued the Study	Mirabegron	Discontinued Early	1		Participants
The Number of Participants Who Completed and Discontinued the Study	Tolterodine Tartrate	Discontinued Early	1		Participants
Change From Baseline in California Verbal Learning Test (CVLT) Score at 8 Weeks	Mirabegron		4.70	95% Confidence Interval 1.13 to 8.27	Score on a Scale
Change From Baseline in California Verbal Learning Test (CVLT) Score at 8 Weeks	Tolterodine Tartrate		1.59	95% Confidence Interval -2.20 to 5.37	Score on a Scale
Change From Baseline in Trail Making Test, Trail A Score at 8 Weeks	Mirabegron		-11.34	95% Confidence Interval -15.57 to -7.11	seconds
Change From Baseline in Trail Making Test, Trail A Score at 8 Weeks	Tolterodine Tartrate		0.67	95% Confidence Interval -3.79 to 5.13	seconds
Change From Baseline in Short Physical Performance Battery (SPPB) Score at 8 Weeks	Mirabegron		-0.39	95% Confidence Interval -1.03 to 0.25	score on a scale
Change From Baseline in Short Physical Performance Battery (SPPB) Score at 8 Weeks	Tolterodine Tartrate		0.24	95% Confidence Interval -0.47 to 0.96	score on a scale

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Mirabegron	12
Overall Study	STARTED	Tolterodine Tartrate	11
Overall Study	COMPLETED	Mirabegron	11
Overall Study	COMPLETED	Tolterodine Tartrate	10
Overall Study	NOT COMPLETED	Mirabegron	1
Overall Study	NOT COMPLETED	Tolterodine Tartrate	1

Source ClinicalTrials.gov

Adverse events32

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Back pain	Musculoskeletal and connective tissue disorders	Mirabegron	0	12	0
other	Back pain	Musculoskeletal and connective tissue disorders	Tolterodine Tartrate	2	11	2
other	Cold/flu	General disorders	Mirabegron	0	12	0
other	Cold/flu	General disorders	Tolterodine Tartrate	1	11	1
other	Constipation	Gastrointestinal disorders	Mirabegron	0	12	0
other	Constipation	Gastrointestinal disorders	Tolterodine Tartrate	3	11	3
other	Dry mouth	General disorders	Mirabegron	0	12	0
other	Dry mouth	General disorders	Tolterodine Tartrate	3	11	3
other	Memory problems/confusion	Nervous system disorders	Mirabegron	0	12	0
other	Memory problems/confusion	Nervous system disorders	Tolterodine Tartrate	1	11	1

1 to 10 of 32Source ClinicalTrials.gov

See all 32 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Mirabegron	0	12
Total, all-cause mortality	Tolterodine Tartrate	0	11
Total, other adverse events	Mirabegron	5	12
Total, other adverse events	Tolterodine Tartrate	6	11
Total, serious adverse events	Mirabegron	0	12
Total, serious adverse events	Tolterodine Tartrate	0	11

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Mirabegron vs Tolterodine Tartrate: deaths from any cause	Trial comparisons
Mirabegron vs Tolterodine Tartrate: serious adverse events	Trial comparisons

Tests3

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as	Source
Trail Making Test A	Secondary outcome	ConductCognition
Trail Making Test B	Secondary outcome	ConductCognition
Verbal Learning	Secondary outcome	ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02436889

GET https://conductscience.org/api/trials/v1/NCT02436889/events?page=2

API reference For AI assistants